# A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

> clinical trial · VERIFIED · 2026-07-06

Status: ACTIVE_NOT_RECRUITING · Sponsor: Janssen Research & Development, LLC · Condition: Leukemia, Lymphocytic, Chronic, B-Cell

- Company: Janssen Research & Development, LLC
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT03462719

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.